pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
raps·1d ago·1 min read
save

EMA starts voluntary data-sharing pilot to boost confidence in new approach methods and cut animal testing

Sep 2, 2026·read at raps ↗RegulatoryPositive

The European Medicines Agency announced a voluntary data submission pilot that allows drug developers to upload data generated by new approach methodologies (NAMs).

The pilot is designed to build regulator confidence in NAM data, with the goal of reducing or replacing traditional animal studies during drug development.

It reflects a wider push by regulators worldwide to lessen reliance on animal testing and encourage alternative methods.

Participation is voluntary, and the EMA hopes shared data will streamline assessments and promote more humane research practices.

source

This writeup was produced by pharmadog from original reporting by raps.

Original headline: “EMA launches data sharing pilot to gain confidence in NAMs, reduce animal testing”

read at raps ↗
72 words · retrieved 40m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 2d agoRecon: Trump announces new pricing deals with midsize biotechs; Novartis pauses CAR-T trials after patient deathsraps
  • 2d agoFDA drafts guidance on assessing impact of hepatic impairment on drug PK/PDraps
  • 2d agoFDA officials review best practices for validating digitally derived endpointsraps
  • 3d agoRecon: FDA approves Protagonist and Takeda’s drug for rare blood cancer; Lilly to buy Merida for up to $2.88Braps
  • 3d agoAsia-Pacific Roundup: India simplifies regulatory framework for outsourced sterilization of medical devicesraps